<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Scriba TJ</dc:creator>
  <dc:creator>Kaufmann SH</dc:creator>
  <dc:creator>Henri Lambert P</dc:creator>
  <dc:creator>Sanicas M</dc:creator>
  <dc:creator>Martin C</dc:creator>
  <dc:creator>Neyrolles O</dc:creator>
  <dc:date>2016</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Live attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial species are in various stages of preclinical or clinical development. In this review, we discuss the vaccine candidates and key factors shaping the development pathway for live and killed WCVs and provide an update on progress.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/116324</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/infdis/jiw228</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27247343</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>The Journal of infectious diseases. - 2016</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">BCG</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">tuberculosis</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">vaccine</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">whole-cell vaccine</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Clinical Trials as Topic</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Drug Evaluation, Preclinical</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Mycobacterium</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Tuberculosis</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Tuberculosis Vaccines</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Vaccines, Attenuated</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Vaccines, Inactivated</dc:subject>
  <dc:title xmlns:ns13="xml" ns13:lang="en">Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>